Assessing the physiological relevance of the bioactivation of tobacco-specific carcinogen NNK and its metabolite NNAL: quantitative analyses of hydrolysis products from their protein adducts under different carcinogen exposure conditions
Carcinogenesis · 09.04.2026 · 47 (2)
DOI: 10.1093/carcin/bgag031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Carcinogenesis, online erschienen am 17.05.2026. Verfasst von Breanne Freeman und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry and Center for Natural Products, Drug Discovery, and Development, College of Pharmacy, University of Florida, Gaine…. Hauptthemen laut MEDLINE: Nitrosamines, Carcinogens, Lung Neoplasms. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Florida Department of Health, NCI NIH HHS, National Cancer Institute of the National Institutes of Health.
Abstract (Originalsprache)
4-(Methyl-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and its major metabolite 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) are tobacco-specific lung carcinogens. NNK is widely used in preclinical models to induce lung tumorigenesis for elucidating carcinogenesis mechanisms and developing preventive agents, because of the high tumour burden in a cost-effective manner. Typical NNK doses employed in these models substantially exceed levels in humans and the routes of administration (e.g. intraperitoneal injection, oral gavage, or delivery via drinking water) differ fundamentally from inhalational exposure through cigarette smoke. At the molecular level, NNK and NNAL undergo metabolic bioactivation by cytochrome P450 enzymes, generating reactive intermediates capable of covalently modifying DNA and proteins, thereby initiating carcinogenesis. NNK and NNAL are also subject to competing metabolism. Their portion undergoing carcinogenic bioactivation is expected to vary as a function of dose and route of exposure, raising concerns about the physiological relevance of these preclinical models. Systematic comparison of NNK and NNAL bioactivation profiles in humans with these preclinical models can help assess their physiological relevance and inform translational application. Using LC–MS/MS methods, this study quantified 4-hydroxy-1-(3-pyridyl)-1-butanone (HPB, an NNK-derived bioactivation hydrolysis product) and 1-(3-pyridyl)-1,4-butanediol (PBD, an NNAL-specific bioactivation hydrolysis product) in lung, liver, and serum samples from two mouse models and in human lung and plasma samples. Marketed differences were observed between NNK intraperitoneal preclinical models and human samples; in contrast, the tobacco smoke-based preclinical model better recapitulates human NNK and NNAL bioactivation. These results provide guidance for the future use of these models in investigating lung carcinogenesis and developing preventive agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry and Center for Natural Products, Drug Discovery, and Development, College of Pharmacy, University of Florida, Gainesville, FL 32610, United States.
- Department of Epidemiology, College of Public Health and Health Professionals & College of Medicine, University of Florida, Gainesville, FL 32610, United States.
- Department of Medicine, Medical School, University of Minnesota, Minneapolis, MN 55455, United States.
- Department of Community Health & Family Medicine, College of Medicine, University of Florida, Gainesville, FL 32610, United States.
- Department of Health Outcome & Biomedical Informatics, College of Medicine, University of Florida, Gainesville, FL 32610, United States.
- UF Department of Psychiatry, College of Medicine, University of Florida, Gainesville, FL 32610, United States.
ORCID-Profile: Tengfei Bian, Naomi Fujioka, Frank A Orlando, Dejana Braithwaite, Ramzi G Salloum, Weizhou Zhang, Chengguo Xing
Förderung
- Florida Department of Health
- NCI NIH HHS
- National Cancer Institute of the National Institutes of Health
- James Robert Spenser Family
- UF Health Cancer Center
Zitieren
APA
Freeman, B., Bian, T., Xu, G., Wheeler, M., Fujioka, N., Malaty, J., Orlando, F. A., Braithwaite, D., Salloum, R. G., Bruijnzeel, A. W., Zhang, W., & Xing, C. (2026). Assessing the physiological relevance of the bioactivation of tobacco-specific carcinogen NNK and its metabolite NNAL: quantitative analyses of hydrolysis products from their protein adducts under different carcinogen exposure conditions. Carcinogenesis, 47(2). https://doi.org/10.1093/carcin/bgag031
Vancouver
Freeman B, Bian T, Xu G, Wheeler M, Fujioka N, Malaty J, et al. Assessing the physiological relevance of the bioactivation of tobacco-specific carcinogen NNK and its metabolite NNAL: quantitative analyses of hydrolysis products from their protein adducts under different carcinogen exposure conditions. Carcinogenesis. 2026;47(2). doi:10.1093/carcin/bgag031
BibTeX
@article{Freeman2026,
author = {Freeman, Breanne and Bian, Tengfei and Xu, Gujie and Wheeler, Meghann and Fujioka, Naomi and Malaty, John and Orlando, Frank A and Braithwaite, Dejana and Salloum, Ramzi G and Bruijnzeel, Adriaan W and Zhang, Weizhou and Xing, Chengguo},
title = {Assessing the physiological relevance of the bioactivation of tobacco-specific carcinogen NNK and its metabolite NNAL: quantitative analyses of hydrolysis products from their protein adducts under different carcinogen exposure conditions},
journal = {Carcinogenesis},
year = {2026},
volume = {47},
number = {2},
doi = {10.1093/carcin/bgag031}
}
EUVIMED